Data / Drug companies / E.r. Squibb & Sons, L.L.C.
E.r. Squibb & Sons, L.L.C.: 51 products in the FDA NDC directory, labeler code 0003
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
E.r. Squibb & Sons, L.L.C. (labeler code 0003) lists 51 products in the FDA National Drug Code Directory, covering 19 finished drugs by generic name. By type: 51 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on August 13, 2026.
The request: Watch E.r. Squibb & Sons, L.L.C. (FDA labeler code 0003): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0003
- Products in commercial distribution
- 51
- Packages
- 73
- Finished drugs by generic name
- 19
- Prescription products
- 51
- Over the counter products
- 0
- Flagged as original packager
- 39 of 39 products that carry the flag
- Started marketing in the last 12 months
- 2
- Earliest marketing start
- June 24, 2003
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 35 | 68.6% |
| Biologics (BLA) | 16 | 31.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 51 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Dasatinib | 6 | 18 |
| Apixaban | 6 | 8 |
| Xanomeline and trospium chloride | 5 | 1 |
| Nivolumab | 4 | 1 |
| Abatacept | 4 | 1 |
| Triamcinolone acetonide | 3 | 77 |
| Atazanavir | 3 | 4 |
| Entecavir | 3 | 15 |
| Repotrectinib | 2 | 1 |
| Aztreonam | 2 | 5 |
| Nivolumab and hyaluronidase-nvhy | 2 | 1 |
| Elotuzumab | 2 | 1 |
| Iberdomide | 2 | 1 |
| Ipilimumab | 2 | 1 |
| Deucravacitinib | 1 | 1 |
| Halcinonide | 1 | 3 |
| Nivolumab and relatlimab-rmbw | 1 | 1 |
| Atazanavir and cobicistat | 1 | 1 |
| Belatacept | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 7 | 13.7% |
| Injection | 7 | 13.7% |
| Tablet, film coated | 5 | 9.8% |
| Capsule | 5 | 9.8% |
| Injection, solution | 5 | 9.8% |
| Injection, powder, lyophilized, for solution | 4 | 7.8% |
| Kit | 4 | 7.8% |
| Injection, suspension | 3 | 5.9% |
| Capsule, coated pellets | 3 | 5.9% |
| Capsule, gelatin coated | 2 | 3.9% |
| Solution | 2 | 3.9% |
| Injection, powder, for solution | 2 | 3.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Kinase Inhibitor | 8 |
| Programmed Death Receptor-1 Blocking Antibody | 7 |
| Corticosteroid | 4 |
| Factor Xa Inhibitor | 4 |
| Protease Inhibitor | 4 |
| Selective T Cell Costimulation Modulator | 4 |
| Cholinergic Muscarinic Agonist | 3 |
| Cholinergic Muscarinic Antagonist | 3 |
| Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 3 |
| Monobactam Antibacterial | 2 |
| Endoglycosidase | 2 |
| SLAMF7-directed Immunostimulatory Antibody | 2 |
| CTLA-4-directed Blocking Antibody | 2 |
| Tyrosine Kinase 2 Inhibitor | 1 |
| Lymphocyte Activation Gene-3 Blocker | 1 |
| Cytochrome P450 3A Inhibitor | 1 |
| Selective T Cell Costimulation Blocker | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Zenbexus | 0003-5710 | Capsule | New drug applications (NDA) | August 13, 2026 |
| Zenbexus | 0003-5700 | Capsule | New drug applications (NDA) | August 13, 2026 |
| Eliquis | 0003-1028 | Tablet, for suspension | New drug applications (NDA) | September 15, 2025 |
| Eliquis sprinkle | 0003-0898 | Capsule | New drug applications (NDA) | September 15, 2025 |
| Opdivo qvantig | 0003-6120 | Injection, solution | Biologics (BLA) | January 2, 2025 |
| Opdivo qvantig | 0003-3120 | Injection, solution | Biologics (BLA) | December 27, 2024 |
| Augtyro | 0003-4160 | Capsule | New drug applications (NDA) | November 1, 2024 |
| Cobenfy | 0003-5200 | Kit | New drug applications (NDA) | September 27, 2024 |
| Cobenfy | 0003-5150 | Kit | New drug applications (NDA) | September 27, 2024 |
| Cobenfy | 0003-1100 | Capsule, coated pellets | New drug applications (NDA) | September 27, 2024 |
| Cobenfy | 0003-0125 | Capsule, coated pellets | New drug applications (NDA) | September 27, 2024 |
| Cobenfy | 0003-0050 | Capsule, coated pellets | New drug applications (NDA) | September 27, 2024 |
| Augtyro | 0003-4040 | Capsule | New drug applications (NDA) | December 5, 2023 |
| Sotyktu | 0003-0895 | Tablet, film coated | New drug applications (NDA) | September 9, 2022 |
| Opdualag | 0003-7125 | Injection | Biologics (BLA) | March 18, 2022 |
| Opdivo | 0003-3756 | Injection | Biologics (BLA) | August 30, 2021 |
| Kenalog-80 | 0003-0315 | Injection, suspension | New drug applications (NDA) | April 12, 2019 |
| Opdivo | 0003-3734 | Injection | Biologics (BLA) | December 8, 2017 |
| ELIQUIS 30-Day Starter Pack | 0003-3765 | Kit | New drug applications (NDA) | November 29, 2017 |
| ELIQUIS 30-Day Starter Pack | 0003-3764 | Kit | New drug applications (NDA) | November 29, 2017 |
| Empliciti | 0003-4522 | Injection, powder, lyophilized, for solution | Biologics (BLA) | November 30, 2015 |
| Empliciti | 0003-2291 | Injection, powder, lyophilized, for solution | Biologics (BLA) | November 30, 2015 |
| Evotaz | 0003-3641 | Tablet | New drug applications (NDA) | January 29, 2015 |
| Opdivo | 0003-3774 | Injection | Biologics (BLA) | December 22, 2014 |
| Opdivo | 0003-3772 | Injection | Biologics (BLA) | December 22, 2014 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.